Database analysis sets stage for a multicenter trial assessing TAVR’s potential role
Analysis used echocardiographic data to assess structural valve deterioration
PARTNER 2 analysis finds few significant effects
Pooling of PARTNER data finds low rates regardless of approach
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
An expert Q&A on degeneration findings from EuroPCR
FDA approvals for valve-in-valve TAVR follow clearance of 3rd-generation valve
Final outcomes report changes treatment paradigm
TAVR an acceptable alternative to surgery in patients at high surgical risk